Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of OCS-05 in Patients with Acute Optic Neuritis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Sep 2025 Results presented in an Oculis Pharma media release
22 Sep 2025 According to an Oculis Pharma media release, data from this trial to be presented in upcoming presentation at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Congress, Thursday, September 25, 2025; 16:30 CET
01 Sep 2025 According to an Oculis Pharma media release,data from this trial will be presented at the 25th European Society of Retina Specialists (EURETINA) Congress, and the Retina Society Annual Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com